Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia.
第一著者: | Armitage, J |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2008
|
類似資料
-
Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia.
著者:: Minhas, R, 等
出版事項: (2009) -
Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
著者:: Neil, A, 等
出版事項: (2003) -
Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
著者:: Neil, H, 等
出版事項: (2003) -
Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
著者:: Neil, H, 等
出版事項: (2004) -
CTCA in children with severe heterozygous familial hypercholesterolaemia: Screening for subclinical atherosclerosis
著者:: M. Doortje Reijman, 等
出版事項: (2024-03-01)